ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, VH184 and VH499.

Trichy: Trichy corporation has enumerated at least 10,000 girls aged 14 years across the city to be vaccinated with the HPV (human papillomavirus vacc.

Automation transforms vaccination into a traceable, well‑controlled operation that supports performance metrics.

Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and ...

ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing: London Saturday, February 28, 2026, 13:00 Hrs [IST] ViiV Heal ...

In healthy, nonpregnant women, the multidose vial of RSVpreF vaccine produces immune responses and safety outcomes comparable ...

For use outside the EU, the regulator backed a single-dose oral approach that treats all stages and could spare patients ...

VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an ...

The results indicate that safety in children under two years was consistent across both RSV seasons receiving Enflonsia.

A small stable of doctors gave V.I.P. medical services to the sex offender and the women around him. Some doctors bent or ...

Thymine modified polymer for delivering DNA into cells. A thymine modified compound, poly (ethylene glycol) (PEG), is bound to DNA through an annealing process, then delivered by intramuscular ...

Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S ...